Physician profile
Mohammed S Ahmed
NPI 1962588061
$1,064,430.23
in general payments reported to CMS, 2019-2025
29 companies · $180K in 2025
The $180K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173K · 2020: $63K · 2021: $142K · 2022: $191K · 2023: $150K · 2024: $166K · 2025: $180K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $357K · Travel and Lodging: $63K · Consulting Fee: $34K · Food and Beverage: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Honoraria: $12K · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $356,786.20 |
| Travel and Lodging | $63,111.27 |
| Consulting Fee | $33,576.25 |
| Food and Beverage | $16,667.86 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,000.00 |
| Honoraria | $12,112.50 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $349,831.32 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $304,857.69 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $99,699.35 | 2021-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $80,524.41 | 2019 | |
| Travere Therapeutics, INC. | $63,112.77 | 2019-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $53,170.58 | 2021-2025 | |
| Ardelyx, INC. | $41,191.10 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,132.34 | 2022-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $17,619.35 | 2022-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $10,985.52 | 2019-2024 | Jynarque |
| Outset Medical INC | $10,209.32 | 2022 | |
| Glaxosmithkline, LLC. | $3,367.62 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $1,552.36 | 2019-2025 | |
| Horizon Therapeutics Plc | $576.90 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $543.71 | 2019-2024 | Auryxia, Vafseo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $532.62 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $532.24 | 2024-2025 | Krystexxa |
| Ceribell, INC. | $187.56 | 2025 | Pocket Eeg Device |
| Genentech, INC. | $149.55 | 2025 | Gazyva |
| Medtronic, INC. | $146.54 | 2022 | |
| Baxter Healthcare | $106.68 | 2019 | |
| Ani Pharmaceuticals, INC. | $79.03 | 2022 | |
| Novo Nordisk INC | $78.62 | 2023-2025 | Ozempic, Rybelsus |
| Exthera Medical Corporation | $74.08 | 2021 | |
| Shire North American Group INC | $66.77 | 2019 | |
| Opko Pharmaceuticals, LLC | $35.08 | 2022 | |
| Vifor Pharma, INC. | $24.87 | 2022 | |
| Genentech USA, INC. | $24.06 | 2025 | Gazyva |
| Alexion Pharmaceuticals, INC. | $18.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.